The heterodimer Fc platform improves structural stability and increases efficacy, thereby enhancing the immune response, for various multi-specific antibodies, including bispecific antibodies.
It allows for flexible arrangement of various antigen target sequences, facilitating more efficient and stable antibody development and enabling rapid development of immuno-cancer drugs.
This platform technology, aimed to enhance the immune response through improved protein function, will provide novel design and engineering strategies.